Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109954 · ClinicalTrials.gov registry record · Phase 3
Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery
A Phase 3 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 3
- Development phase
- 120
- Enrollment target
NCT00109954 is a Phase 3 study that has completed, run by University of Pittsburgh. The registered enrollment target is 120 participants.
The verdict
NCT00109954, a Phase 3 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 120 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. In this case, chemotherapy is given through the artery (hepatic artery) that brings blood to the tumor. Chemoembolization kills tumor cells by blocking the blood flow to the tumor and keeping chemotherapy drugs near the tumor. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether hepatic arterial chemoembolization with cisplatin is more effective than internal radiation therapy in treating liver cancer. PURPOSE: This randomized phase III trial is studying hepatic arterial chemoembolization with cisplatin to see how well it works compared to internal radiation therapy in treating patients with advanced liver cancer that cannot be removed by surgery.
Interventions
- DRUG cisplatin
- RADIATION brachytherapy
- RADIATION yttrium Y 90 glass microspheres
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2005-02 |
| Est. Completion | 2005-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109954
The ClinicalTrials.gov registry entry for NCT00109954 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which cisplatin is the first listed.
NCT00109954 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109954 about?
NCT00109954 is a clinical study titled "Hepatic Arterial Chemoembolization With Cisplatin or Internal Radiation Therapy in Treating Patients With Advanced Liver Cancer That Cannot Be Removed By Surgery". RATIONALE: Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. In this case, chemotherapy is given through the artery (hepatic artery) that brings blood to the tumor. Chemoembolization...
What is the current status of trial NCT00109954?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 120 participants. The study started on 2005-02. Estimated completion is 2005-12.
What interventions are being tested in trial NCT00109954?
The interventions under investigation include: cisplatin (DRUG), brachytherapy (RADIATION), yttrium Y 90 glass microspheres (RADIATION).
Who is sponsoring clinical trial NCT00109954?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.